SutroVax competitors

SutroVax Competitors include MyoKardia, Athersys, Ironwood Pharmaceuticals and Biogen.
Add company...
SutroVax
SutroVax
SutroVax is a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious diseases.
MyoKardia
MyoKardia
MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.
Athersys
Athersys
Athersys, a biopharmaceutical company, discovers and develops therapeutic products for the treatment of several disease indications.
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, an entrepreneurial pharmaceutical company, develops drugs for gastrointestinal and cardiovascular diseases.
Biogen
Biogen
Biogen develops, markets and manufactures therapies for people living with serious neurological, autoimmune and rare diseases.
Founding Date
Founding Date
2013
Founding Date
2012
Founding Date
1995
Founding Date
N/A
Founding Date
1978
Type
Type
Private
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Foster City, US HQ
Locations
South San Francisco, US HQ
Locations
Cleveland, US HQ
Canton, US
Locations
Cambridge, US HQ
Locations
Cambridge, US HQ
Employees
Employees
403% increase
Employees
1024% increase
Employees
6610% increase
Employees
7308% increase
Employees
7,300
Valuation ($)
Valuation ($)
N/A
Valuation ($)
2.1 b
Valuation ($)
272.2 m
Valuation ($)
1.8 b
Valuation ($)
63.4 b
Twitter followers
Twitter followers
N/A
Twitter followers
387
Twitter followers
953
Twitter followers
3.1 k
Twitter followers
19.4 k

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
$22.5m (FY, 2017)
Revenue (est.)
$3.7m (FY, 2017)
Revenue (est.)
$298.3m (FY, 2017)
Revenue (est.)
$11.4b (FY, 2016)
Net income
Net income
N/A
Net income
($46m) (FY, 2017)
Net income
N/A
Net income
($116.9m) (FY, 2017)
Net income
$3.7b (FY, 2016)

Operating

Patents (US)
Patents (US)
N/A
Patents (US)
4 (FY, 2017)
Patents (US)
21 (FY, 2016)
Patents (US)
N/A
Patents (US)
N/A
Phase I Trials Products
Phase I Trials Products
N/A
Phase I Trials Products
2 (FY, 2017)
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
4 (FY, 2016)
Phase II Trials Products
Phase II Trials Products
N/A
Phase II Trials Products
1 (FY, 2017)
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
10 (FY, 2016)

Funding

Total funding raised
Total funding raised
$ 171m
Total funding raised
$ 98m
Total funding raised
$ 9m
Total funding raised
$ 284m
Total funding raised
N/A
For sources of this data, please see the company profileDownload Excel

View company profiles

MyoKardia
HQ
South San Francisco, US
Employees
102↑ 4% increase

MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.

View company
Athersys
HQ
Cleveland, US
Employees
66↑ 10% increase

Athersys, a biopharmaceutical company, discovers and develops therapeutic products for the treatment of several disease indications.

View company
Ironwood Pharmaceuticals
HQ
Cambridge, US
Employees
730↑ 8% increase

Ironwood Pharmaceuticals, an entrepreneurial pharmaceutical company, develops drugs for gastrointestinal and cardiovascular diseases.

View company
Biogen
HQ
Cambridge, US
Employees
7,300

Biogen develops, markets and manufactures therapies for people living with serious neurological, autoimmune and rare diseases.

View company